Matthew Johnson
Professor of Psychiatry
Papers
Trials
Key Impact
A leading clinical researcher who has advanced evidence on the therapeutic potential and safety of classic psychedelics—particularly psilocybin—for addiction and mental health outcomes through clinical trials, survey research and methodological guidance.
Background & Research
Matthew W. Johnson is an established researcher in human hallucinogen science whose work spans clinical trials, survey-based epidemiology and experimental psychopharmacology. He has co‑authored and led influential studies examining psilocybin‑assisted interventions for substance use disorders (notably tobacco smoking cessation), naturalistic and clinical outcomes following classic psychedelic use (including reductions in alcohol use, psychological distress and suicidality), and dose‑related human effects of non-classic compounds such as salvinorin A. Johnson has collaborated extensively with other prominent investigators in the field to characterise both therapeutic mechanisms and adverse or challenging reactions, and has contributed to safety guidance for human hallucinogen research.